United Therapeutics | UTHR - Cash And Equivalent


United Therapeutics reported $1.28B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Amarin USD 131.06M 3.6M Mar/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Bayer EUR 6.67B 774M Dec/2025
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
United Therapeutics USD 1.28B 277.4M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026